Table 1.
The 13 guanidinobenzoyl- or aminidinobenzoyl-containing drugs studied in this work.
| DrugBank ID | Drug Name | Status with FDA | Primary Indication |
|---|---|---|---|
| DB00738 | Pentamidine | Approved | For the treatment of pneumocystis pneumonia |
| DB03808 | Hexamidine | Approved | For the treatment of acanthamoebiasis |
| DB05038 | Anatibant | Investigational | For the treatment of traumatic brain injuries |
| DB05476 | WX-UK1 | Investigational | For the treatment in solid tumors |
| DB06472 | Fradafiban | Investigational | For the treatment in angina |
| DB06635 | Otamixaban | Investigational | For the treatment of thrombosis |
| DB12120 | Avoralstat | Investigational | For the prevention of hereditary angioedema |
| DB12598 | Nafamostat | Investigational | Used as an anticoagulant in patients with disseminative blood vessel coagulation, hemorrhagic lesions, and hemorrhagic tendencies |
| DB13000 | PCI-27483 | Investigational | For the treatment of pancreatic cancer, ductal adrenocarcinoma, and exocrine pancreatic cancer |
| DB13296 | Propamidine | Investigational | For the treatment of Acanthamoeba infection |
| DB13729 | Camostat | Investigational | For the treatment of chronic pancreatitis and drug-induced lung injury |
| DB14726 | Dabigatran | Investigational | For the treatment and prevention of blood clots and prevention of stroke in people with atrial fibrillation |
| DB14753 | Hydroxystilbamidine | Approved | For the treatment of nonprogressive blastomycosis of the skin and other mycoses |
Note: The table is ranked by DrugBank ID. Camostat and Nafamostat have been approved in Japan but have not been approved by the FDA.